

Suggested Reading Materials

- Burks JS, Johnson KP, eds. *Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation*. New York: Demos, 2000.
- Calabresi PA. Diagnosis and management of multiple sclerosis. *Am Fam Physician*. 2004;70:1935-1944.
- Costello K, Halper J. *Multiple Sclerosis: Key Issues in Nursing Management: Adherence, Cognition, Quality of Life*, 3rd Edition. Expert Medical Education. 2010.
- Costello K, Halper J. *Advanced Practice Nursing in Multiple Sclerosis: Advanced Skills, Advancing Responsibilities*, 3rd Edition. Expert Medical Education. 2010.
- Courtney AM, Treadaway K, Remington G, et al. Multiple sclerosis. *Med Clin North Am*. 2009;93:451-476.
- Halper J, ed. *Advanced Concepts in Multiple Sclerosis Nursing Care*. New York: Demos Medical Publishing, 2007.
- Halper J, Holland NJ, eds. *Comprehensive Nursing Care in Multiple Sclerosis*. New York: Springer Publishing Company, 2011.
- Harris C, Halper J. *Best Practices in Nursing Care: Disease Management, Pharmacological Treatment, Nursing Research*, 3rd Edition. Bioscience Communications. 2008.

Adherence

- Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. *Medscape J Med*. 2008;10:225.
- Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. *J Neurosci Nurs*. 2001;33:231-239.
- Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. *J Neurosci Nurs*. 2003;35:163-170.
- Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. *Patient Prefer Adherence*. 2010;4:1-9.
- Twook S, Nippert I, Scherer P, et al. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. *Curr Med Res Opin*. 2007;23:1209-1215.

Diagnosis and Prognosis

- Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. *Lancet Neurol*. 2008;7:615-625.
- Confavreux CV, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis. *Brain*. 2003;126:770-782.

- Daumer M, Neuhaus A, Lederer C, et al. Prognosis of the individual course of disease--steps in developing a decision support tool for multiple sclerosis. *BMC Med Inform Decis Mak.* 2007;7:11-16.
- Fazekas F, Soelberg-Sorensen P, Comi G, et al. MRI to monitor treatment efficacy in multiple sclerosis. *J Neuroimaging.* 2007;17(suppl 1): 50S-55S.
- Li DK, Li MJ, Traboulsee A, et al. The use of MRI as an outcome measure in clinical trials. *Adv Neurol.* 2006;98:203-226.
- Rovira A, León A. (2008) MR in the diagnosis and monitoring of multiple sclerosis: an overview. *Eur J Radiol.* 2008;67:409-414.
- Simon B, Schmidt S, Lukas C, et al. Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. *Eur Radiol.* 2010;20:1675-1683.
- Stroud N, Minahan C, Sabapathy S. The perceived benefits and barriers to exercise participation in persons with multiple sclerosis. *Disabil Rehabilitation.* 2009;31:2216-2222.
- Tremlett HP, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. *Neurol Rep.* 2006;66:172-177.
- Zivadinov R, Stosic M, Cox JL, et al. The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. *J Neurol.* 2008;255(suppl 1):61-74.

Epidemiology

- Noonan CW, Williamson DM, Henry JP, et al. The prevalence of multiple sclerosis in 3 US communities. *Prev Chronic Dis.* 2010;7: A12.
- Warren S, Turpin K, Janzen W, et al. Variance in health-related quality of life explained by socio-demographic and MS-related factors: data from the North American Research Committee on Multiple Sclerosis. Paper presented at: European Committee for Treatment and Research in Multiple Sclerosis 2010 Annual Meeting; October 15, 2010; Göteborg, Sweden.

Pathogenesis

- Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. *N Engl J Med.* 2006;354:942-955.
- Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. *Radiology.* 2000;214:665-670.
- Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. *Cell.* 2010;140:918-934.
- Goverman J. Autoimmune T cell responses in the central nervous system. *Nat Rev Immunol.* 2009;9:393-407.
- Kasper LH, Shoemaker J. Multiple sclerosis immunology: The healthy immune system vs the MS immune system. *Neurology.* 2010;74(suppl 1):S2-S8.

Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. *Brain*. 2007;130:1089-1104.

Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. *N Engl J Med*. 2009;361:888-898.

Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. *Am J Pathol*. 2008;172:146-155.

Patient Management

Brown TR, Kraft GH. Exercise and rehabilitation for individuals with multiple sclerosis. *Phys Med Rehabilitation Clin N Am*. 2005;16(2):513-555.

Burks JS, Bigley GK, Hill HH. Rehabilitation challenges in multiple sclerosis. *Ann Indian Acad Neurol*. 2009;12:296-306.

Dalgas U, Stenager E, Jakobsen J, et al. Fatigue, mood and quality of life improve in MS patients after progressive resistance training. *Mult Scler*. 2010;16:480-490.

Fraser R, Johnson E, Ehde D, et al. *Patient self-management in multiple sclerosis*. University of Washington Multiple Sclerosis Rehabilitation Research and Training Center Web site. http://msrrtc.washington.edu/resources/CMSC_WhitePaper.pdf. Accessed February 4, 2011.

Halper J. Comprehensive care in multiple sclerosis - a patient-centered approach. *Eur Neurol*. 2008;3:72-74.

Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales. *J Neurol Neurosurg Psychiatry*. 2005;76(11):1539-1543.

Kalb R. Multiple Sclerosis: A Focus on Rehabilitation. 4th Ed. National Multiple Sclerosis Society. Available at: www.nationalmssociety.org/for-professionals/download.aspx?id=22556.

Lisak RP, Korngold S. Insights for practice: where mechanism of action meets patient management. *Neurology*. 2010;74(suppl 1):S70-S73.

McCullagh R, Fitzgerald AP, Murphy RP, Mater GC: Long-term benefits of exercising on quality of life and fatigue in multiple sclerosis patients with mild disability: a pilot study. *Clin Rehabilitation*. 2008;22(3):206-214.

Motl RW, McAuley E, Snook M: Physical activity and multiple sclerosis: a meta-analysis. *Mult Scler*. 2005;11:459-463.

Petajan ET, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. *Ann Neurol*. 1996;39:432-441.

Provance PG. Physical therapy in multiple sclerosis rehabilitation. *National Multiple Sclerosis Society. Clinical Bulletin*. 2008. Available at: www.nationalmssociety.org/download.aspx?id=163

Provance PG. Rehabilitation philosophy in MS care. Presented at the Consortium of Multiple sclerosis Centers 2010 Annual Meeting. Available at: <http://iomsrt.mscares.org/clinical-page/slide-presentations>.

Rietberg MB, Brooks D, Uitdehaag BMJ, et al. Exercise therapy for multiple sclerosis. *Cochrane Database Systematic Reviews* (Online) 2005;1:CD003980.

Symptomatic Management

Ben-Zacharia AB. Therapeutics for multiple sclerosis symptoms. *Mt Sinai J Med*. 2011;78(2):176-191.

Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. *Sleep*. 2010;33(8):1061-1067.

Cohen BA. Identification, causation, alleviation, and prevention of complications (ICAP): an approach to symptom and disability management in multiple sclerosis. *Neurology*. 2008;71(24 Suppl 3):S14-20.

Di Fabio RP, Soderberg J, Choi T, et al. Extended outpatient rehabilitation: Its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. *Arch Phys Med Rehabilitation*. 1998;79:141-146.

Hasselkorn JK, Balsdon RC, Fry WD, et al. Overview of spasticity management in multiple sclerosis: evidence-based management strategies for spasticity treatment in multiple sclerosis. *J Spinal Cord Med*. 2005;28:173-197.

Kinnman J, Andersson U, Kinnman Y, et al. Temporary improvement of motor function in patients with multiple sclerosis after treatment with a cooling suit. *J Neurol Rehabilitation*. 1997;11:109-114.

Messinis L, Kosmidis MH, Lyros E, et al. Assessment and rehabilitation of cognitive impairment in multiple sclerosis. *Int Rev Psychiatry*. 2010;22:22-34.

Norton C, Chelvanayagam S. Bowel problems and coping strategies in people with multiple sclerosis. *Br J Nurs*. 2010;19:220-226.

Samkoff LM, Goodman AD. Symptomatic management in multiple sclerosis. *Neurol Clin*. 2011;29(2):449-463.

Souza A, Kelleher A, Cooper R, et al. Multiple sclerosis and mobility-related assistive technology: systematic review of literature. *J Rehabilitation Res Dev*. 2010;47:213-223.

Therapy

Bielekova B, Becker BL. Monoclonal antibodies in MS: mechanisms of action. *Neurology*. 2010;74(suppl 1):S31-S40.

Brandes DW, Callender T, Lathi E, et al. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. *Curr Med Res Opin*. 2009;25:77-92.

Caon C, Perumal J, Tselis A, et al. Twice weekly versus daily glatiramer acetate: results of a randomized, rater-blinded prospective clinical trial and MRI study in relapsing-remitting MS. Paper presented at: 2010 American Academy of Neurology Annual Meeting; April 13, 2010; Toronto, Ontario, Canada. Abstract S11.002.

- Chofflon M. Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach? *BioDrugs*. 2005;19:299-308.
- Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. *N Engl J Med*. 2008;359:1786-1801.
- Coles A. Alemtuzumab reverses pre-existing disability in relapsing-remitting multiple sclerosis patients independent of relapse history. Paper presented at: European Committee for Treatment and Research in Multiple Sclerosis 2009 Annual Meeting; September 10, 2009; Düsseldorf, Germany.
- Coles A. Alemtuzumab treatment benefit is durable: primary efficacy outcomes of CAMMS223 at 4 years. Paper presented at: European Committee for Treatment and Research in Multiple Sclerosis 2009 Annual Meeting; September 11, 2009; Düsseldorf, Germany.
- Coles A. Alemtuzumab long-term safety and efficacy: five years of the CAMMS223 trial. Paper presented at: European Committee for Treatment and Research in Multiple Sclerosis 2010 Annual Meeting; October 14, 2010; Göteborg, Sweden.
- Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. *Neurology*. 2008;71(suppl 3):S3-S7.
- Coyle PK. Disease-modifying agents in multiple sclerosis. *Ann Indian Acad Neurol*. 2009;12:273-282.
- Fox E. Long-term follow-up of immune thrombocytopenia after treatment of multiple sclerosis patients with alemtuzumab in CAMMS223. Paper presented at: 2010 American Academy of Neurology Annual Meeting; April 13, 2010; Toronto, Ontario, Canada. Abstract P05.036.
- Fox EJ. Emerging oral agents for multiple sclerosis. *Am J Manag Care*. 2010;16:S219-S226.
- Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. *N Engl J Med*. 2010;362:416-426.
- Giovannoni G, Comi G, Cook S, et al. Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets, in the double-blind, 96-week CLARITY study. Paper presented at: 2010 American Academy of Neurology Annual Meeting; April 13, 2010; Toronto, Ontario, Canada. Abstract S21.008.
- Girouard N, Théorêt G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. *Can J Neurosci Nurs*. 2008;30:18-25.
- Goodman A. Alemtuzumab improves disability in MS patients and prevents relapse but platelet counts should be monitored. *Neurol Today*. 2007;7:15.
- Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. *Ann Neurol*. 2010;68:295-303.
- Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N Engl J Med*. 2008;358: 676-688.
- Jeffrey S. Rituximab phase 2/3 trial fails to meet primary end point in primary progressive MS. Medscape Today Web site. <http://www.medscape.com/viewarticle/573131>. Published April 16, 2008. Accessed February 4, 2011.

- Jeffrey S. Fingolimod receives FDA approval as first oral MS treatment. Medscape Today Web site. <http://www.medscape.com/viewarticle/729172>. Published September 22, 2010. Accessed February 4, 2011.
- Johnson KP. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. *Ther Clin Risk Manag*. 2010;6:153-172.
- Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. *N Engl J Med*. 2006;355:1124-1140.
- Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. *Lancet*. 2008;372:1463-1472.
- Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med*. 2010;362:387-401.
- Merck Serono announces initiation of the ORACLE MS trial to evaluate cladribine tablets in patients at risk of developing multiple sclerosis. Medical News Today Web site. <http://www.medicalnewstoday.com/articles/122047.php>. Published September 19, 2008. Accessed February 4, 2011.
- Oral laquinimod for multiple sclerosis granted fast track status by FDA. Medical News Today Web site. <http://www.medicalnewstoday.com/articles/139148.php>. Published February 16, 2009. Accessed February 4, 2011.
- Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*. 2003;348:15-23.
- Minagar A, Alexander JS, Sahraian MA, et al. Alemtuzumab and multiple sclerosis: therapeutic application. *Expert Opin Biol Ther*. 2010;10:421-429.
- Morrow T. Therapy optimization for targeted therapies. *J Manag Care Med*. 2009;9:28-31.
- Neuhaus O, Kieseier BC, Hartung HP. Mitoxantrone (Novantrone) in multiple sclerosis: new insights. *Expert Rev Neurother*. 2004;4:17-26.
- O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. *Neurology*. 2006;66:894-900.
- O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. *Neurology*. 2009;72:73-79.
- O'Connor PW, Goodman AD, Kappos L, et al. (2010) Updated efficacy and safety of natalizumab in patients who participated in the STRATA study. Paper presented at: European Committee for Treatment and Research in Multiple Sclerosis 2010 Annual meeting; October 14, 2010; Göteborg, Sweden.
- O'Connor P, Polman C, Hohlfeld R, et al. Oral fingolimod (FTY720) vs placebo in relapsing-remitting multiple sclerosis: 24-month clinical efficacy results from a randomized, double-blind, placebo-

controlled, multicenter phase III study (FREEDOMS). Paper presented at: 2010 American Academy of Neurology Annual Meeting; April 13, 2010; Toronto, Ontario, Canada.

Patel A, Patel J, Ikwuagwu J. Treatment of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. *J Antimicrob Chemother.* 2010;65:2489-2492.

Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med.* 2006;354:899-910.

Rammohan KW, Shoemaker J. Emerging multiple sclerosis oral therapies. *Neurology.* 2010;74(suppl 1): S47-S53.

Rieckmann P, Traboulsee A, Devonshire V, et al. Escalating immunotherapy of multiple sclerosis. *Ther Adv Neurol Disord.* 2008;1:181-192.

Rojas MA, Carlson NG, Miller TL, et al. Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. *Ther Adv Neurol Disord.* 2009;2:291-297.

Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. *N Engl J Med.* 2006;354:911-923.

Russek SB. Specialty pharmacy's role in REMS, FDA's new drug safety program. *Formulary.* 2009;44:300-308.

Information on natalizumab (marketed as Tysabri). US Food and Drug Administration Web site. <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107198.htm>. Published September 2009. Accessed February 4, 2011.

Drugs at FDA. US Food and Drug Administration Web site. <http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA>. Accessed February 4, 2011.

van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. *Neurology.* 1997;49:351-357.

Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. *Lancet Neurol.* 2010;9:381-390.